Ocugen and Histogenics have entered into a definitive merger agreement that will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under the Ocugen name, according to a press release.
Under the merger agreement, Ocugen stockholders will become the majority owners of Histogenics’ outstanding common stock.
“This transaction with Ocugen reflects the continued commitment of our management team and board of directors to deliver value to stockholders and make a difference in patients’ lives,” Adam Gridley, president of Histogenics, said
Uncategorized